Septerna Emerges With $100m To Target Undruggable GPCRs
Start-Up Pairs Structural Insights With Computational Tools
Septerna’s platform purifies G-coupled protein receptors (GPCR) to identify new drug targeting sites and then uses technologies such as machine learning to find novel compounds against hard-to-reach GPCRs.
